Forge Co-founder Presents New Approaches to Treat Infections at the 255th American Chemical Society National Meeting

San Diego, California, March 19, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing [...]

March 19th, 2018|

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference

-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC [...]

October 31st, 2017|

Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas

- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - [...]

October 17th, 2017|



Recent Tweets